28 April 2017
Notice of publication of annual financial report
IntegraGen informs its shareholders and the financial community that its 2016 Annual Financial Report has been filed with the AMF.
21 April 2017
IntegraGen Announces 2016 Annual Results: Increase in operating revenues and significant improvement in operating income (+22%)
IntegraGen has announced its financial results for the year ending December 31, 2016. The financial statements were validated by the Company’s Board of Directors on April 20, 2017.
08 March 2017
Laboratoire CERBA signs licensing agreement with IntegraGen to commercialize miR-31-3p tumor expression test
IntegraGen SA and Laboratoire CERBA announced the signing of a licensing agreement allowing Laboratoire CERBA to develop and provide a test based on IntegraGen’s proprietary miR-31-3p biomarker to prescribing clinicians in France, Benelux, Middle East and Africa. Laboratoire CERBA will develop this test to complement its existing portfolio (…) »
03 February 2017
IntegraGen announces successful completion of a € 3.7 million capital increase
IntegraGen today announced that it has successfully completed a capital increase with cancellation of preferential subscription rights, reserved for a category of investors in the amount of € 3.7 million.
Objectives of Fundraising
The funds received will permit IntegraGen to accelerate its development by (…) »
14 October 2016
IntegraGen Reports Revenues for First Half of 2016
IntegraGen today announced its sales for the first half 2016. Sales for IntegraGen’s business totaled € 2.8 million as of June 30, 2016, and increase of 10% compared to the first half of 2015.
Financials
Sales of € 2.8 million, a 10% increase vs. H1 2015 Operational result +14% (…) »10 October 2016
New Data on IntegraGen’s miR-31-3p Biomarker Featured in Presentation at 2016 ESMO Congress
Data presented concludes that miR-31-3p expression is predictive of anti-EGFR therapy effect on objective response, depth of response, and early tumor shrinkage in patients with metastatic colorectal cancer enrolled in prospective, randomized FIRE-3 Trial.
07 July 2016
IntegraGen reports strong revenue growth during first half of 2016
IntegraGen has announced its sales for the first half 2016. The company reported strong growth for its clinical research and microbiology genomics businesses and stability in its genomic services business for research activities with a significant increase in orders across all genomic activities.
29 June 2016
AP-HP and IntegraGen agree to develop a common platform for high-throughput sequencing
The Greater Paris University Hospitals (AP-HP) and IntegraGen announced today an agreement to develop a high-throughput sequencing platform (exome and whole genome) to be utilized for research projects and clinical research initiatives. This three-year research partnership aligns with a major objective of AH-HP’s 2015-2019 Strategic Plan related to (…) »
06 June 2016
IntegraGen Presents Positive Data at 2016 ASCO Meeting on the Role of microRNA Biomarker miR-31-3p
IntegraGen presented positive clinical results on its miR-31-3p biomarker during the 2016 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago. The data presented demonstrates that IntegraGen’s proprietary miR-31-3p biomarker is predictive for both survival and treatment response in patients receiving anti-EGFR therapy.
(…) »
08 April 2016
IntegraGen announces 2015 financial results
IntegraGen today announced its financial results for the year ended 31 December 2015.
The financial statements were reviewed by the Company’s Board of Directors during a meeting held on April 7, 2016.